Ahmet Zengin
Research Subjects
Ahmet Zengin has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- İbRahim Kale
University of Health Sciences, İstanbul Ümraniye Training and Research Hospital, Türkiye
2 shared publications - Anıl Koçman
En yüksek alt kategorisini oluşturmakta olup Cerrahi Onkoloji Bölümü Patoloji Bölümü Avrupa Kanser Jinekolojik Onkoloji Cerrahisi Bölümü
1 shared publication - Arife Ebru Taşcı
Department of Gynecologic Oncology, Ankara Bilkent City Hospital, University of Health Sciences, 06800 Ankara, Turkey
1 shared publication - Arzu Bostancı Durmuş
UNIVERSITY OF HEALTH SCIENCES, ANKARA KEÇİÖREN EDUCATION AND RESEARCH HOSPITAL
1 shared publication - Ayşe Buran
Ankara Bilkent City Hospital
1 shared publication - Ayşe Rumeysa Aydoğan Demir
Faculty of Medicine, Department of Medical Oncology, Ondokuz Mayıs University, Samsun, Turkey
1 shared publication
Latest Publications
- 30 March 2026
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
- Vol. 230 (04) , 349-352
Pulmonary Alveolar Microlithiasis in Pregnancy: A Case Report and Review of the Literature
- 30 March 2026
- Published by Georg Thieme Verlag KG in Zeitschrift für Geburtshilfe und Neonatologie
- Vol. 230 (04) , 349-352
Pulmonary Alveolar Microlithiasis in Pregnancy: A Case Report and Review of the Literature
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (5) , e20252178
Early colposcopy in non-16/18 high-risk human papillomavirus positivity with normal cytology
SUMMARY OBJECTIVE: Very few clinical studies have been done to evaluate the potential clinical benefit of utilizing early colposcopy in women with normal Pap smear cytology but positive for high-risk human papillomavirus types other than human papillomavirus 16 or human papillomavirus 18 in a screening population for cervical cancer. The aim of this study was to compare two follow-up strategies and assess the need for colposcopy at the initial visit, based on cytology, human papillomavirus testing, and colposcopic findings at 1 year, among study participants. METHODS: In total, 122 women who had negative Pap smears and were positive for high-risk types of human papillomavirus (not human papillomavirus 16/18) were randomly allocated to two groups via simple computer-generated randomization. Notably, one group had a colposcopic examination when they were first diagnosed (61), and the other group had standard Pap/human papillomavirus follow-up without a colposcopic examination (61). All women in both groups had repeat Pap and human papillomavirus testing and a colposcopic examination after 1 year. RESULTS: Rates of loop electrosurgical excision procedure application were similar between groups (11.5 and 8.2%; p=0.343). So early colposcopy has enabled the treatment of high-grade squamous intraepithelial lesion lesions without increasing the number of loop electrosurgical excision procedures. CONCLUSION: In women who had negative cytology yet positive high-risk human papillomavirus types other than human papillomavirus 16/18, there was no statistically significant difference in either high-risk human papillomavirus persistence, abnormal cytology rates, or loop electrosurgical excision procedure requirements at a 1-year follow-up after having their colposcopy performed early vs. delayed assessments. This suggests that these patients can be appropriately managed with risk-based follow-up care.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 72 (5) , e20252178
Open AccessEarly colposcopy in non-16/18 high-risk human papillomavirus positivity with normal cytology
SUMMARY OBJECTIVE: Very few clinical studies have been done to evaluate the potential clinical benefit of utilizing early colposcopy in women with normal Pap smear cytology but positive for high-risk human papillomavirus types other than human papillomavirus 16 or human papillomavirus 18 in a screening population for cervical cancer. The aim of this study was to compare two follow-up strategies and assess the need for colposcopy at the initial visit, based on cytology, human papillomavirus testing, and colposcopic findings at 1 year, among study participants. METHODS: In total, 122 women who had negative Pap smears and were positive for high-risk types of human papillomavirus (not human papillomavirus 16/18) were randomly allocated to two groups via simple computer-generated randomization. Notably, one group had a colposcopic examination when they were first diagnosed (61), and the other group had standard Pap/human papillomavirus follow-up without a colposcopic examination (61). All women in both groups had repeat Pap and human papillomavirus testing and a colposcopic examination after 1 year. RESULTS: Rates of loop electrosurgical excision procedure application were similar between groups (11.5 and 8.2%; p=0.343). So early colposcopy has enabled the treatment of high-grade squamous intraepithelial lesion lesions without increasing the number of loop electrosurgical excision procedures. CONCLUSION: In women who had negative cytology yet positive high-risk human papillomavirus types other than human papillomavirus 16/18, there was no statistically significant difference in either high-risk human papillomavirus persistence, abnormal cytology rates, or loop electrosurgical excision procedure requirements at a 1-year follow-up after having their colposcopy performed early vs. delayed assessments. This suggests that these patients can be appropriately managed with risk-based follow-up care.
- Open Access
- 10 November 2025
- Published by Academician Publishing
Olgularla Kadın Hastalıkları ve Doğum II
- 10 November 2025
- Published by Academician Publishing
Open AccessOlgularla Kadın Hastalıkları ve Doğum II
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (9) , e20250639
A new scoring system to predict the success of single-dose methotrexate therapy in ectopic pregnancy
SUMMARY OBJECTIVE: Methotrexate remains the most commonly used agent for the medical management of ectopic pregnancy. The aim of this study was to develop a novel scoring system to predict the efficacy of single-dose methotrexate treatment in ectopic pregnancy. METHODS: In this retrospective study, information on patients diagnosed with ectopic pregnancy between January 2012 and December 2023 was obtained from the hospital information system. Notably, 156 patients received a single dose of methotrexate for ectopic pregnancy treatment and met the study criteria. Almost 117 of those who were successful in single-dose methotrexate treatment constituted the successful methotrexate treatment group. The other 39 cases who failed single-dose methotrexate treatment constituted the failed methotrexate treatment group. A new scoring system was developed based on six parameters, including serum human chorionic gonadotropin level, gestational week, and ultrasound findings. RESULTS: According to the scoring system, the total score was significantly higher in the group in which methotrexate treatment failed compared to the group with successful treatment (4 points versus 2 points, respectively, p<0.001). In receiver operating characteristic analysis, the optimal cut-off value for the scoring system was determined as 2.5, with 92% sensitivity and 78% specificity (AUC=0.804, 95%CI 0.731–0.877). The overall success rate of single-dose methotrexate treatment was 75%. However, when only patients with a score below the cut-off value of 2.5 were considered, the success rate of single-dose methotrexate treatment in ectopic pregnancy increased to 90.5%. CONCLUSION: This new scoring system significantly enhances the ability to predict outcomes of methotrexate therapy, allowing for faster decision-making regarding surgical intervention.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 71 (9) , e20250639
Open AccessA new scoring system to predict the success of single-dose methotrexate therapy in ectopic pregnancy
SUMMARY OBJECTIVE: Methotrexate remains the most commonly used agent for the medical management of ectopic pregnancy. The aim of this study was to develop a novel scoring system to predict the efficacy of single-dose methotrexate treatment in ectopic pregnancy. METHODS: In this retrospective study, information on patients diagnosed with ectopic pregnancy between January 2012 and December 2023 was obtained from the hospital information system. Notably, 156 patients received a single dose of methotrexate for ectopic pregnancy treatment and met the study criteria. Almost 117 of those who were successful in single-dose methotrexate treatment constituted the successful methotrexate treatment group. The other 39 cases who failed single-dose methotrexate treatment constituted the failed methotrexate treatment group. A new scoring system was developed based on six parameters, including serum human chorionic gonadotropin level, gestational week, and ultrasound findings. RESULTS: According to the scoring system, the total score was significantly higher in the group in which methotrexate treatment failed compared to the group with successful treatment (4 points versus 2 points, respectively, p<0.001). In receiver operating characteristic analysis, the optimal cut-off value for the scoring system was determined as 2.5, with 92% sensitivity and 78% specificity (AUC=0.804, 95%CI 0.731–0.877). The overall success rate of single-dose methotrexate treatment was 75%. However, when only patients with a score below the cut-off value of 2.5 were considered, the success rate of single-dose methotrexate treatment in ectopic pregnancy increased to 90.5%. CONCLUSION: This new scoring system significantly enhances the ability to predict outcomes of methotrexate therapy, allowing for faster decision-making regarding surgical intervention.